Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

NCT02817633 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT02817633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02817633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 8, 2016
Completion date
March 1, 2027
Enrollment
463 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms